Insights Archive
Filter by:
November 3, 2024
Humira® biosimilars in focus
For years, Humira® (adalimumab) has been a significant driver of healthcare costs due to its high price and utilization. With the introduction of several Humira biosimilars, learn how ClearScript has been monitoring the landscape and adapting strategies to provide members access to cost-effective therapy options for better health.
September 19, 2024
Fiduciary Stewardship: Patients not Profits
Why are the Big Three the most significant cost drivers in pharmacy benefits today? Because they put profits before patients. Fortunately, ClearScript is different. Listen to this coffee chat to learn how you can ensure your PBM is putting your members before profits.
July 23, 2024
What Tribal Groups need to know about the Big Three PBMs
Listen to learn why Tribal Nations are especially at risk when working with big PBMs that don’t keep their best interests at heart.
July 15, 2024
ClearScript Solutions: MedEmpower™ Fuel
To help plans manage the rising cost of diabetes and weight management while improving member health, ClearScript offers our MedEmpower Fuel™ program.
July 15, 2024
Drug Spotlight: liraglutide (brand name Victoza)
On June 24, 2024, drug manufacturer Teva Pharmaceuticals announced the launch of an authorized generic formulation of Novo Nordisk’s Victoza (liraglutide). This marks the first generic glucagon-like peptide-1 (GLP-1) agonist available in the U.S. market.
July 15, 2024
ClearScript: Innovating Transparency from the Start
ClearScript was an early pioneer of transparency in pharmacy benefit management. Unlike the Big Three PBMs, we put patients before profits.
June 7, 2024
Biosimilars and your pharmacy benefit plan – Frequently Asked Questions
With the rapid-fire launch of multiple new biosimilars, health plan managers struggle to understand the impact to their pharmacy benefit plan. Listen to get answers from ClearScript’s clinical account team on frequently asked questions about biosimilars.
April 3, 2024
GLP-1s, losing weight or losing money?
GLP-1s are a hot topic in health plans due to their high-price tag and coverage complexity. Following up on ClearScript’s recent GLP-1 webinar, this podcast will answer some new questions and provide additional updates about this drug class.
April 3, 2024
Rezdiffra (resmetirom)
On March 14, 2024, drug manufacturer Madrigal Pharmaceuticals announced the approval of Rezdiffra™, a new, first in class oral therapy for nonalcoholic steatohepatitis (NASH). This disease, which impacts an estimated 6-8 million people in the U.S., is underdiagnosed and if left untreated, it can cause serious liver complications. Read more about this approval and its implications.